Hy-Vee announces participation in Pharmacy Saver
WEST DES MOINES, Iowa — Midwestern supermarket chain Hy-Vee will offer 366 commonly prescribed generic prescription drugs for as little as $2 to select Medicare beneficiaries through a program offered in collaboration with UnitedHealthcare, Hy-Vee said.
The chain said it joined Pharmacy Saver, which UnitedHealthcare started last year. UnitedHealthcare is the country’s largest Medicare Part D insurer, and the program is available at more than 6,000 locations throughout the country.
“Hy-Vee is always looking for ways to help our pharmacy customers save money on their prescriptions,” Hy-Vee VP pharmacy operations Bob Egeland said. “With the Pharmacy Saver program, Medicare patients don’t have to sacrifice convenience, flexibility or friendly personalized service in order to get the lowest prices on the medications they need.”
Like many retailers, Hy-Vee offers a generic discount program, whereby customers can fill 30-day prescriptions for $4 and 90-day prescriptions for $10.
GenerationRx youth toolkit addresses Rx abuse among teens
DUBLIN, Ohio — The Cardinal Health Foundation has strengthened its alliance with the Ohio State University College of Pharmacy to address prescription drug abuse among teens.
The Cardinal Health Foundation and the college’s GenerationRx youth toolkit provides healthcare providers, pharmacists, parents, teachers, youth group leaders and other concerned citizens with unique, interactive resources to educate teens about the realities and dangers of prescription drug abuse, the Cardinal Health Foundation said.
The toolkit — which is available for download at CardinalHealth.com/GenerationRx — complements the Generation Rx toolkit the two organizations developed for adults.
“Cardinal Health customers and employees are passionate about educating the public about the dangers of prescription drug abuse and misuse, and our new youth toolkit was created in direct response to their interest in speaking directly to teens about this growing public health issue,” said Jessica Lineberger, community relations manager for Cardinal Health.
Watson confirms patent challenge over generic Exalgo
MORRISTOWN, N.J. — Drug maker Watson Pharmaceuticals said it has filed a regulatory approval application for a generic painkiller, challenging the patent that covers the branded version.
Watson announced Tuesday that it had filed an application with the Food and Drug Administration seeking approval for hydromorphone hydrochloride extended-release tablets in the 8-mg, 12-mg and 16-mg strengths. The drug is a generic version of Mallinckrodt’s Exalgo.
Pursuant to the Hatch-Waxman Act of 1984, which created the approval pathway for generic pharmaceutical drugs, Mallinckrodt filed a patent infringement suit against Watson last week. The suit puts a stay on final approval of Watson’s version of the drug until April 2013, or until the two companies reach a settlement. The patents covering the drug expire in July 2014, according to the FDA.